BBIO three-lens brief
Evidence-based stock research on BBIO. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
Outperforming SPY by 21.3pp over 30 days. · Currently unprofitable on a trailing basis — no P/E multiple available.
- Outperforming SPY by 21.3pp over 30 days.
- Currently unprofitable on a trailing basis — no P/E multiple available.
- Analyst mean target $106.85 — 34% above current (20 analysts).
- Negative free cash flow last quarterly (-$287.13M).
- Reported earnings on 2026-10-29.
BBIO closed at $79.54 (+1.11%) as of 2026-11-12. Market cap: $15.49B. Price is above the 50-day MA and above the 200-day MA. Positives: outperforming SPY by 21.3pp over 30 days.; analyst mean target $106.85 — 34% above current (20 analysts).. Concerns: currently unprofitable on a trailing basis — no P/E multiple available.; negative free cash flow last quarterly (-$287.13M).. Last quarter: Revenue $353.17M, net income -$83.00M, free cash flow -$287.13M.
Why three lenses on BBIO, not one.
A single reasoning model has blind spots it doesn’t know about. We examine BBIO across Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://www.clearpathinvest.app/embed/BBIO" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath BBIO brief"></iframe>